The pathophysiology of treatment-related nausea and vomiting in cancer patients: Current models

Indian Journal of Physiology and Pharmacology

Volumn 48, Issue 3, 2004, Pages 256-268

  Shelke, Abhay R ^a   Mustian, Karen M ^a   Morrow, Gary R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

5 hydroxytryptamine; Anticipatory nausea vomiting; Antiemetics; Chemotherapy; Conditioning; Nausea; Neurotransmitters; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APOMORPHINE; BROMOCRIPTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FLUOROURACIL; GALLIUM NITRATE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVODOPA; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 3 ANTAGONIST;

ADRENAL INSUFFICIENCY; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; DRUG EFFICACY; HUMAN; NAUSEA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TASTE DISORDER;

ANTINEOPLASTIC AGENTS; HUMANS; NAUSEA; NEOPLASMS; VOMITING;

EID: 3242703995     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Miller AD. Central mechanisms of vomiting. Dig Dis Sci 1999; 44: 39S-43S.
2. Allan SG. Mechanisms and management of chemotherapy-induced nausea and vomiting. Blood Rev 1987; 1: 50-57.
3. Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. Am Med Sci 1987; 293: 34-44.
4. Jenns K. Importance of nausea. Cancer Nurs 1994; 17: 488-493.
5. Morrow GR, Roscoe JA, Hynes HE, Flynn PJ, Pierce HI, Burish T. Progress in reducing anticipatory nausea and vomiting: A study of community practice. Support Care in Cancer 1998; 6: 46-50.
6. Andrykowski MA, Jacobsen PB, Marks E et al. Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer 1988; 62: 2607-2613.
7. Hickok JT, Roscoe JA, Morrow GR. The role of patients' expectations in the development of anticipatory nausea related to chemotherapy for cancer. J Pain Symptom Manage 2001; 22: 843-850.
8. Morrow GR, Dobkin PL. Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behavioral interventions. Clin Psychol Rev 1988; 8: 517-556.
9. Morrow GR, Roscoe JA. Anticipatory nausea and vomiting: Models, mechanisms and management. In Dicato M, (ed). Medical management of cancer treatment induced emesis. London: Martin Dunitz, 1997; 149-166.
10. Morrow GR, Roscoe JA, Hynes HE, Flynn PJ, Pierce HI, Burish T. Progress in reducing anticipatory nausea and vomiting: A study of community practice. Support Care in Cancer 1998; 6: 46-50.
11. Coates A, Abraham S, Kaye SB et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-208.
12. Griffin AM, Butow PN, Coates AS et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-195.
13. Steward DJ. Cancer therapy, vomiting and antiemetics. Can J Physiol Pharmacol 1990; 68: 304-313.
14. Miller AD, Leslie RA: The area postrema and vomiting. Front Neuroendocrinol 1994; 15: 301-320.
15. Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from emetic vagal afferents and the area postrema to the pattern generator for the emetic act in dogs. Neuroscience Research 1992; 14: 166-179.
16. Ison PJ, Peroutka SJ. Neurotransmitter Receptor Binding Predict Antiemetic Efficacy and Side Effects. Cancer Treat Rep 1986; 70: 637-641.
17. Young RW. Mechanisms and treatment of radiation-induced nausea and vomiting. In Davis CJLB, (ed). Nausea and Vomiting: Mechanisms and Treatment. Berlin: Springer-Verlag, 1986: 96-109.
18. Fortner CL, Finley RS, Grove WR. Combination antiemetic therapy in the control of chemotherapy-induced emesis. Drug Intell Clin Pharm 1985; 19: 21-24.
19. Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn AL. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. [comment]. J Clin Oncol 1990; 8: 1721-1727.
20. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. [comment]. N Eng J Med 1990; 322: 810-816.
21. Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose Metoclopramide: Randomized trials with placebo and Prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Eng J Med 1981; 305: 905-909.
22. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33: 691-697.
23. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials Group. N Eng J Med 1999; 340: 190-195.
24. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. Journal of Clinical Oncology 2003; 21: 4112-4119.
25. de Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Journal of Clinical Oncology 2003; 21: 4105-4111.
26. Kobrinsky NL. Regulation of Nausea and Vomiting in Cancer Chemotherapy. Am J Pediatr Hematol/ Oncol 1988; 10: 209-213.
27. Dullemond-Westland AC, Neijt JP, Nortier JW, Sitsen JM. Buprenorphine versus domperidone in chemotherapy-induced emesis: a pilot study. Radiotherapy & Oncology 1986; 6: 127-133.
28. Ettinger DS. Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Semin Oncol 1995; 22: 6-18.
29. Harris JG. Nausea, vomiting and cancer treatment. Ca Cancer J Clin 1978; 28: 194-201.
30. Morrow GR. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 1985; 55: 2766-2770.
31. Fetting JH, Wilcox PM, Sheidler VR. Tastes associated with parenteral chemotherapy for breast cancer. Cancer Treat Rep 1985; 69: 1249-1251.
32. Cassileth BR, Lusk EJ, Bodenheimer BJ, Barber JM, Jochimsen P, Morrin-Taylor B. Chemotherapeutic toxicity-the relationship between patients' pretreatment expectations and posttreatment results. Am J Clin Oncol 1985; 8: 419-425.
33. Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983; 25: 8-17.
34. Morrow GR, Andrews PL, Hickok JT, Stern R. Vagal changes following cancer chemotherapy: implications for the development of nausea. Psychophysiology 2000; 37: 378-384.
35. Hu S, Grant WF, Stern RM, Koch KL. Motion sickness severity and physiological correlates during repeated exposures to a rotating optokinetic drum. Aviat Space Environ Med 1991; 62: 308-314.
36. Uijtdehaage SH, Stern RM, Koch KL. Effects of eating on vection-induced motion sickness, cardiac vagal tone, and gastric myoelectric activity. Psychophysiology 1992; 29: 193-201.
37. Morrow GR, Hickok JT, DuBeshter B, Lipshultz SE. Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy-induced nausea. J Autonc Nerv Syst 1999; 78: 57-63.
38. Berntson GG, Cacioppo JT, Quigley KS. Autonomic determinism: the modes of autonomic control, the doctrine of autonomic space, and the laws of autonomic constraint. Psychological Review 1991; 98: 459-487.
39. Morrow GR, Angel C, DuBeshter B. Autonomic changes during cancer chemotherapy induced nausea and emesis. Br J Cancer Suppl 1992; 19: S42-S45.
40. Fredrikson M, Hursti T, Salmi P et al. Conditioned nausea after cancer chemotherapy and autonomic nervous system conditionability. Scand J Psychol 1993; 34: 318-327.
41. Hursti T, Fredrikson M, Steineck G, Borjeson S, Peterson C. Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids. Br J Cancer 1993; 68: 112-114.
42. Seymour MT. The pharmacokinetics and pharmacodynamics of chemotherapeutic agents. In Andrews PLR, Sanger GJ, (eds). Emesis in Anti-Cancer Therapy. London: Chapman & Hall Medical, 1993; 9-44.
43. Roila F, Ballatori E, Contu A, Tateo S, Ricci S, Ionta MT, Picece V, Nuzzo A, Locatelli MC, Scagliotti G, Tonato M. Optimal dose of intravenous (iv) dexamethasone (DEX) in the prevention of cisplatin (CDDP)-induced acute emesis: A double-blind randomized study. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 50a.
44. Morrow GR, Hickok JT, Andrews PL, Stern RM. Reduction in serum cortisol after platinum based chemotherapy for cancer: A role for the HPA axis in treatment-related nausea ? Psychophysiology 2002; 39: 491-495.
45. Morrow GR, Rosenthal SN. Models, mechanisms and management of anticipatory nausea and emesis. Oncology 1996; 53 Suppl 1: 4-7.
46. Morrow GR, Lindke J, Black PM. Anticipatory nausea development in cancer patients: Replication and extension of a learning model. Br J Psychol 1991; 82: 61-72.
47. Hickok JT, Roscoe JA, Morrow GR. The role of patients' expectations in the development of anticipatory nausea related to chemotherapy for cancer. J Pain Symptom Manage 2001; 22: 843-450.
48. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68: 585-588.
49. Andrykowski MA, Redd WH, Hatfield AK. Development of anticipatory nausea: a prospective analysis. J Consult Clin Psychol 1985; 53: 447-454.
50. Alba E, Bastus R, de Andres L, Sola C, Paredes A, Lopez Lopez JJ. Anticipatory nausea and vomiting: Prevalence and predictors in chemotherapy patients. Oncology 1989; 46: 26-30.
51. Morrow GR. Susceptibility to motion sickness and the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy. Cancer Treat Rep 1984; 68: 1177-1178.
52. Nesse RN, Carli T, Curtis GC, Kleinman PD. Pretreatment nausea in cancer chemotherapy: A conditioned response. Psychosom Med 1980; 42: 33-36.
53. Watson M, Meyer L, Thomson A, Osofsky S. Psychological factors predicting nausea and vomiting in breast cancer patients on chemotherapy. Eur J Cancer 1998; 34: 831-837.
54. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Eng J Medicine 1982; 307: 1476-1480.
55. Redd WH, Andresen GV, Minagawa RY. Hypnotic control of anticipatory emesis in patients receiving cancer chemotherapy. J Consult Clin Psychol 1982; 50: 14-19.
56. Redd WH, Jacobsen PB, Die-Trill M, Dermatis H, McEvoy M, Holland JC. Cognitive/attentional distraction in the control of conditioned nausea in pediatric cancer patients receiving chemotherapy. J Consult Clin Psychol 1987; 55: 391-395.
57. Greene PG, Seime RJ. Stimulus control of anticipatory nausea in cancer chemotherapy. J Behavior Ther Exp Psychiatry 1987; 18: 61-64.